JAK inhibitor linked to PAH in case study

The oral JAK inhibitor tofacitinib has been linked to pulmonary arterial hypertension in a patient seen at a Sydney clinic. In a letter in the Journal of Clinical Rheumatology, a team of cardiologists and rheumatologists from Sydney Adventist Hospital and Macquarie University present the case of a 32 year old female with a provisional diagnosis ...

Already a member?

Login to keep reading.

© 2021 the limbic